BACKGROUND: We sought to investigate the relation between the Arg389Gly polymorphism in the human beta1-adrenergic receptor (ADRB1) gene and acute myocardial infarction (AMI). It was previously reported that augmented sympathetic activity might play an important role as a trigger of AMI by enhanced hemodynamic or mechanical forces through ADRB1 activation. Recently, a common polymorphism has been identified at amino acid position 389 (Arg or Gly) of the human ADRB1, within a region important for receptor-Gs protein coupling and subsequent agonist-stimulated adenylyl cyclase activation. METHODS: To investigate the relation between the Arg389Gly polymorphism in the ADRB1 gene and AMI, we genotyped 354 patients with AMI and 354 age- and sex-matched control subjects by use of polymerase chain reaction amplification and the restriction fragment length polymorphism analysis. RESULTS: The prevalence of the Arg389 homozygote (CC) genotype was significantly more frequent in patients with AMI than in control subjects (68.1% vs 47.2%, P <.0001). In logistic regression models, the odds ratio (OR) of Arg389 homozygote (CC) versus Arg389Gly heterozygote (CG) + Gly389 homozygote (GG) genotypes between control subjects and patients with AMI was 2.86 (95% CI 1.92-4.26, P =.0001). The association of the Arg389Gly polymorphism of ADRB1 with AMI was statistically significant and independent of other risk factors. CONCLUSION: Our findings suggest that the genotype of Arg389Gly polymorphism in the human ADRB1 gene is associated with AMI.
BACKGROUND: We sought to investigate the relation between the Arg389Gly polymorphism in the humanbeta1-adrenergic receptor (ADRB1) gene and acute myocardial infarction (AMI). It was previously reported that augmented sympathetic activity might play an important role as a trigger of AMI by enhanced hemodynamic or mechanical forces through ADRB1 activation. Recently, a common polymorphism has been identified at amino acid position 389 (Arg or Gly) of the humanADRB1, within a region important for receptor-Gs protein coupling and subsequent agonist-stimulated adenylyl cyclase activation. METHODS: To investigate the relation between the Arg389Gly polymorphism in the ADRB1 gene and AMI, we genotyped 354 patients with AMI and 354 age- and sex-matched control subjects by use of polymerase chain reaction amplification and the restriction fragment length polymorphism analysis. RESULTS: The prevalence of the Arg389 homozygote (CC) genotype was significantly more frequent in patients with AMI than in control subjects (68.1% vs 47.2%, P <.0001). In logistic regression models, the odds ratio (OR) of Arg389 homozygote (CC) versus Arg389Gly heterozygote (CG) + Gly389 homozygote (GG) genotypes between control subjects and patients with AMI was 2.86 (95% CI 1.92-4.26, P =.0001). The association of the Arg389Gly polymorphism of ADRB1 with AMI was statistically significant and independent of other risk factors. CONCLUSION: Our findings suggest that the genotype of Arg389Gly polymorphism in the humanADRB1 gene is associated with AMI.
Authors: Jonathan G Zaroff; Ludmila Pawlikowska; Jacob C Miss; Sirisha Yarlagadda; Connie Ha; Achal Achrol; Pui-Yan Kwok; Charles E McCulloch; Michael T Lawton; Nerissa Ko; Wade Smith; William L Young Journal: Stroke Date: 2006-05-25 Impact factor: 7.914
Authors: K K Khush; L Pawlikowska; R L Menza; B A Goldstein; V Hayden; J Nguyen; H Kim; A Poon; A Sapru; M A Matthay; P Y Kwok; W L Young; L A Baxter-Lowe; J G Zaroff Journal: Am J Transplant Date: 2012-09-20 Impact factor: 8.086
Authors: Amir M Nia; Evren Caglayan; Natig Gassanov; Tom Zimmermann; Orhan Aslan; Martin Hellmich; Firat Duru; Erland Erdmann; Stephan Rosenkranz; Fikret Er Journal: PLoS One Date: 2010-07-02 Impact factor: 3.240
Authors: Michael A Pacanowski; Issam Zineh; Rhonda M Cooper-Dehoff; Carl J Pepine; Julie A Johnson Journal: Am J Hypertens Date: 2009-04-30 Impact factor: 2.689
Authors: M A Pacanowski; Y Gong; R M Cooper-Dehoff; N J Schork; M D Shriver; T Y Langaee; C J Pepine; J A Johnson Journal: Clin Pharmacol Ther Date: 2008-07-09 Impact factor: 6.875